Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 28, 2017; 23(44): 7899-7905
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Published online Nov 28, 2017. doi: 10.3748/wjg.v23.i44.7899
Table 2 Association of baseline characteristics of the patients with sustained virological response treated with sofosbuvir+ribavirin (First group) n (%)
| Baseline characteristics (n = 847) | ETR (n = 847), overall ETR = 100% | SVR (n = 840), overall SVR = 99.17% | Relapse (n = 7), overall relapse rate = 0.83% |
| Age (yr) | |||
| ≤ 40 (n = 435) | 435 (100) | 433 (99.54) | 2 (0.46) |
| > 40 (n = 412) | 412 (100) | 407 (98.79) | 5 (1.21) |
| Previous antiviral treatment history | |||
| Naïve (n = 91) | 91(100) | 89 (97.80) | 2 (2.20) |
| Treated (n = 756) | 756 (100) | 751 (99.34) | 5 (0.66) |
| Gender | |||
| Male (n = 310) | 310 (100) | 309 (99.68) | 1 (0.32) |
| Female (n = 537) | 537 (100) | 531 (98.88) | 6 (1.12) |
- Citation: Iqbal S, Yousuf MH, Yousaf MI. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol 2017; 23(44): 7899-7905
- URL: https://www.wjgnet.com/1007-9327/full/v23/i44/7899.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i44.7899